Compare Stocks → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:AMAMNASDAQ:MOLN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMAMAmbrx Biopharma$28.00$27.94$6.55▼$28.15$1.77B-1.922.12 million shsN/AMOLNMolecular Partners$3.88$4.06$3.32▼$7.32$141.11M0.775,020 shs254 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMAMAmbrx Biopharma0.00%0.00%0.00%+0.86%+208.37%MOLNMolecular Partners0.00%+16.87%-7.62%-16.74%-41.83%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMAMAmbrx Biopharma0.0986 of 5 stars1.30.00.00.00.61.70.6MOLNMolecular Partners0.1955 of 5 stars2.01.00.00.00.00.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMAMAmbrx Biopharma2.50Moderate Buy$24.13-13.84% DownsideMOLNMolecular Partners2.00Hold$4.5015.98% UpsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMAMAmbrx Biopharma$7.40M238.95N/AN/A$3.05 per share9.18MOLNMolecular Partners$7.84M18.00N/AN/A$5.41 per share0.72Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMAMAmbrx Biopharma-$78MN/A0.00N/AN/AN/AN/AN/AN/AMOLNMolecular Partners-$69.04M-$2.12N/AN/AN/A-885.11%-31.10%-27.93%5/10/2024 (Estimated)Latest AMAM and MOLN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023MOLNMolecular PartnersN/A-$0.68-$0.68-$0.68N/A$1.17 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMAMAmbrx BiopharmaN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMAMAmbrx BiopharmaN/A13.2813.28MOLNMolecular PartnersN/A13.3513.35OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMAMAmbrx Biopharma77.28%MOLNMolecular Partners26.55%Insider OwnershipCompanyInsider OwnershipAMAMAmbrx Biopharma0.64%MOLNMolecular Partners5.93%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAMAMAmbrx Biopharma8763.15 million62.75 millionOptionableMOLNMolecular Partners16736.37 million34.21 millionNot OptionableAMAM and MOLN HeadlinesSourceHeadlineMolecular Partners (NASDAQ:MOLN) Stock Price Down 5.9%americanbankingnews.com - April 26 at 2:36 AMLife Science Cares Launches in Switzerlandglobenewswire.com - April 19 at 11:12 AMWe Think Molecular Partners (VTX:MOLN) Needs To Drive Business Growth Carefullyfinance.yahoo.com - April 18 at 2:20 AMMolecular Partners Announces All Board Proposals Approved at the Annual General Meetingglobenewswire.com - April 17 at 11:12 AMBeyond Benign, MilliporeSigma partner on green chemistrybizjournals.com - April 4 at 7:47 PMMolecular Partners Publishes Invitation to Annual General Meeting 2024globenewswire.com - March 26 at 9:26 AMLeerink Partners Keeps Their Hold Rating on Molecular Partners (MOLN)markets.businessinsider.com - March 21 at 9:32 AMMolecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023globenewswire.com - March 14 at 4:00 PMMolecular Partners AG (spons. ADRs) hosts conference call for investorsmarkets.businessinsider.com - March 13 at 1:23 PMThe past three years for Molecular Partners (VTX:MOLN) investors has not been profitablefinance.yahoo.com - March 13 at 8:22 AMMolecular Partners wins dismissal of securities lawsuituk.investing.com - March 2 at 10:41 PMMolecular Partners Announces Dismissal of Class Action Lawsuitglobenewswire.com - March 1 at 4:17 PMMolecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentationsglobenewswire.com - March 1 at 4:00 PMNew £1.5m Centre could unlock the secrets of diseases, molecule-by-moleculealphagalileo.org - February 5 at 8:31 AMStrategic Alliances In The Low Molecular Hyaluronic Acid Marketopprairie.com - February 4 at 12:58 AMMolecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 7 at 4:40 PMMolecular Partners, Orano to collaborate on RDT therapies for cancermsn.com - January 5 at 5:30 PMMolecular Partners AG (6ML0.MU)ca.finance.yahoo.com - December 31 at 7:59 PMMolecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meetingfinance.yahoo.com - December 10 at 2:06 PMMolecular Partners AG ADR MOLNmorningstar.com - November 11 at 8:05 AMMolecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Expositionfinance.yahoo.com - November 2 at 7:43 AMMolecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summitfinance.yahoo.com - November 1 at 5:39 AMShareholders in Molecular Partners (VTX:MOLN) are in the red if they invested five years agofinance.yahoo.com - October 5 at 5:03 AMMolecular Partners Reports H1 2023 Corporate Highlights and Financialsfinance.yahoo.com - August 24 at 5:16 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAmbrx BiopharmaNYSE:AMAMAmbrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.Molecular PartnersNASDAQ:MOLNMolecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.